New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
10:01 EDTCNCE, HAR, LH, DGX, LINTA, HSNI, IBP, TLMR, EGRX, FLXNOn The Fly: Analyst Initiation Summary
Concert Pharmaceuticals (CNCE) initiated with a Buy at UBS and an Outperform at JMP Securities... Eagle Pharmaceuticals (EGRX) initiated with a Buy at Cantor and an Overweight at Piper Jaffray... Talmer Bancorp (TLMR) initiated with an Outperform at Keefe Bruyette, an Overweight at JPMorgan, a Strong Buy at Raymond James and an Outperform at RBC Capital... HSN, Inc. (HSNI) initiated with a Buy at UBS... Installed Building Products (IBP) initiated with a Buy at Deutsche Bank and a Neutral at SunTrust... Liberty Interactive (LINTA) initiated with a Buy at UBS and Craig-Hallum... Flexion (FLXN) initiated with a Buy at Needham... LabCorp (LH) assumed with a Neutral at Piper Jaffray... Quest Diagnostics (DGX) assumed with a Neutral at Piper Jaffray... Harman (HAR) initiated with an Outperform at Raymond James.
News For CNCE;EGRX;TLMR;IBP;HSNI;LINTA;DGX;LH;HAR;FLXN From The Last 14 Days
Check below for free stories on CNCE;EGRX;TLMR;IBP;HSNI;LINTA;DGX;LH;HAR;FLXN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
08:04 EDTLHLabCorp, ARCA Biopharma present GENETIC-AF poster at HFSoA meeting
Subscribe for More Information
September 15, 2014
07:21 EDTLHHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 12, 2014
16:12 EDTCNCEBiotechnology Value Fund reports 6.7% passive stake in Concert Pharmaceuticals
September 11, 2014
13:05 EDTHSNI, LINTALiberty Media CEO says eyeing more deals, sees cable consolidation 'inevitable'
Subscribe for More Information
September 9, 2014
16:12 EDTFLXNFlexion issued composition of matter patent for lead candidate FX006
Flexion Therapeutics announced that the U.S. Patent and Trademark Office has issued a composition of matter patent, entitled "Corticosteroids for the Treatment of Joint Pain," which provides coverage for FX006, the company's lead clinical product candidate. FX006 is a novel, non-opioid, sustained-release, intra-articular formulation of triamcinolone acetonide.
September 8, 2014
16:06 EDTDGXQuest Diagnostics: More people testing positive for chikungunya virus in U.S.
Subscribe for More Information
08:36 EDTLHARCA Biopharma, LabCorp announce GENETIC-AF poster presentation
Subscribe for More Information
September 5, 2014
08:53 EDTFLXNFlexion price target raised to $28 from $25 at Summer Street
Subscribe for More Information
September 4, 2014
09:24 EDTLINTACitadel Advisors reports 5.8% passive stake in Liberty Interactive
Subscribe for More Information
09:05 EDTFLXNFlexion FDA guidance a 'significant positive,' says Summer Street
Subscribe for More Information
08:07 EDTLINTAFTD Companies announces early termination of HSR waiting period
FTD Companies (FTD) and Liberty Interactive (LINTA) announced that the companies received notice of early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or HSR, with respect to FTD's pending acquisition of Liberty's Provide Commerce floral and gifting businesses. Under the terms of the transaction agreement, Provide Commerce will become a wholly-owned subsidiary of FTD. The transaction is valued at $430M, consisting of 10.2M shares of FTD common stock representing approximately 35% of the combined company and $121M in cash. FTD and Liberty expect to complete the transaction by the end of 2014. Termination of the HSR waiting period satisfies one of the conditions required for completion of the transaction. The transaction remains subject to approval by FTD's stockholders and other customary conditions.
06:58 EDTFLXNFlexion to host conference call
Conference call to discuss an update on the new clinical development plan for FX006 will be held on September 4 at 8:30 am. Webcast Link
September 3, 2014
16:12 EDTFLXNFlexion advances FX006 development plan by one year after FDA meeting
Subscribe for More Information
10:00 EDTDGXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:17 EDTDGXQuest Diagnostics upgraded to Conviction Buy from Buy at Goldman
Goldman upgraded Quest Diagnostics to Conviction Buy from Buy based on expectations for improving industry volumes, cost cutting focus, margin expansion potential, and capital allocation. Price target raised to $78 from $66.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use